- Boehringer Ingelheim's interferon-free hepatitis C treatment portfolio strengthened by promising Phase II data
- 2013년 11월 4일 09:40
- Boehringer Ingelheim International GmbH
- New efficacy and safety data for Pradaxa® (dabigatran etexilate) to be announced at American Heart Association’s Scientific Sessions 2013
- 2013년 11월 13일 17:16
- Boehringer Ingelheim International GmbH
- Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim (Photo: Business Wire)
- 2013년 11월 13일 17:20
- Boehringer Ingelheim International GmbH
- Boehringer Ingelheim Logo
- 2013년 11월 13일 17:20
- Boehringer Ingelheim International GmbH
- Reversal of dabigatran-induced anticoagulation with antibody fragment (Fab), measured using Diluted Thrombin Time (dTT)
- 2013년 11월 19일 09:15
- Boehringer Ingelheim International GmbH
- Pradaxa(R) - Now approved in over 100 countries worldwide for people living with an irregular heart beat. Providing best brain protection against their biggest fear: a stroke
- 2014년 3월 7일 18:00
- Boehringer Ingelheim International GmbH
- Importance of Preventing COPD Exacerbations
- 2018년 3월 30일 14:25
- Boehringer Ingelheim International GmbH
- DYNAGITO® One of the Largest Studies to Date of Exacerbations in COPD
- 2018년 3월 30일 14:25
- Boehringer Ingelheim International GmbH